Robert Stansbury, MD
Pulmonary Disease · Morgantown, WVNPI 1871756247
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.9%), food and beverage and education — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Resmed Corp at 58.3% of the total. Reporting peaked in 2022 at $1,636 and has fallen 82.9% since, to $280 in 2025.
Across 38 payments — averaging $66.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Resmed Corp$1K
- Harmony Biosciences LLC$309
- Jazz Pharmaceuticals Inc.$255
- ZOLL Respicardia, Inc.$168
- Boehringer Ingelheim$119
- Inspire Medical Systems, Inc.$80
- plus $117 from 3 others
What the payments were for
- Consulting fees$1,43057%
- Food & beverage$88135%
- Education$2008%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Resmed Corp | 3 | $1,463 |
| Harmony Biosciences LLC | 23 | $309 |
| Jazz Pharmaceuticals Inc. | 3 | $255 |
| ZOLL Respicardia, Inc. | 3 | $168 |
| Boehringer Ingelheim | 1 | $119 |
| Inspire Medical Systems, Inc. | 1 | $80 |
| Philips North America LLC | 1 | $65 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $39 |
| Vapotherm Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,511 in reported general payments places this provider in the 65th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XyremSodium Oxybate | 12 | $258,187 |
| XywavSodium,calcium,mag,pot Oxybate | 12 | $244,190 |
| BelsomraSuvorexant | 13 | $5,470 |
| Armodafinil | 16 | $1,086 |
| Modafinil | 22 | $654 |
| Temazepam | 12 | $232 |
| Doxepin Hcl | 13 | $125 |
| Clonazepam | 18 | $115 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Morgantown
- Roger AbrahamsMorgantown$133K
- Peter KochupuraMorgantown$22K
- Sidharth BhasinMorgantown$7K
- Andrzej JaworskiMorgantown$5K
- Kyle ChapmanMorgantown$5K
- Haroon AhmedMorgantown$4K
- Mehdi FarishtaMorgantown$4K
- Sarah HadiqueMorgantown$4K
- Srinivasa PotlaMorgantown$3K
- Joseph RussoMorgantown$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.